View in EDS

98LBA Late Breaking - Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors

Saved in:
Bibliographic Details
Title: 98LBA Late Breaking - Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors
Authors: Macchini, M.1 (AUTHOR), Garralda, E.2 (AUTHOR), Fiedler, W.3 (AUTHOR), Del Conte, G.1 (AUTHOR), Rolling, C.3 (AUTHOR), Kebenko, M.3 (AUTHOR), Klinghammer, K.F.4 (AUTHOR), Ahrens-fath, I.5 (AUTHOR), Habel, B.5 (AUTHOR), Baumeister, H.5 (AUTHOR), Zurlo, A.5 (AUTHOR), Ochsenreiter, S.4 (AUTHOR)
Source: European Journal of Cancer. 2020 Supplement 2, Vol. 138, pS5-S6. 2p.
Database: Academic Search Ultimate
Be the first to leave a comment!
You must be logged in first